Investigational drug · Phase 3
HRS-6209
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Advanced Unresectable or Metastatic Breast Cancer of Adults.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
9
Any phase or sponsor naming "HRS-6209"
First trial start
2024
Aug 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-6209", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Unresectable or Metastatic Breast Cancer
- Breast Cancer
- Advanced Unresectable or Metastatic Breast Cancer of Adults
- Advanced Solid Tumors
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-6209" as an intervention, largest first.
- A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast CancerPivotal-lookingNot yet recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07894328 · 1,050 participants (planned) · Start Nov 20, 2026 · Primary completion Jul 30, 2031
Drug: HRS-6209 + Letrozole; Dalpciclib/Palbociclib + Letrozole/Anastrozole · For: Breast Cancer
Sites: Tianjin, China
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsPivotal-lookingRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06555068 · 528 participants (planned) · Start Aug 12, 2024 · Primary completion Dec 2027
Drug: HRS-6209 in Combination with Fulvestrant; HRS-6209 in Combination with HRS-1358 and 9 more · For: Advanced Unresectable or Metastatic Breast Cancer; Advanced Solid Tumors
Sites: Shanghai, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06679036 · 300 participants (planned) · Start Jan 21, 2025 · Primary completion Oct 30, 2026
Drug: HRS-2189; Fluvustat and 3 more · For: Advanced Unresectable or Metastatic Breast Cancer
Sites: Harbin, China; Zhengzhou, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07389733 · 180 participants (planned) · Start Mar 27, 2026 · Primary completion Dec 2028
Drug: HRS-6208 Capsule; HRS-6209 Capsule and 3 more · For: Advanced Unresectable or Metastatic Breast Cancer of Adults
Sites: Dalian, China; Chengdu, China
- A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast CancerRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06974929 · 80 participants (planned) · Start May 22, 2025 · Primary completion Dec 2026
Drug: HRS-6209 Capsules; Letrozole Tablets and 1 more · For: Breast Cancer
Sites: Tianjin, China
- A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid TumorsActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05781048 · 56 participants · Start Mar 23, 2023 · Primary completion Dec 30, 2026
Drug: HRS-6209 · For: Advanced Solid Tumors
Sites: Shanghai, China
- A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy ParticipantsActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07610148 · 21 participants · Start Jun 8, 2026 · Primary completion Sep 2026
Drug: HRS-6209 Capsule (old formulation); HRS-6209 Capsule (new formulation) · For: Breast Cancer
Sites: Fuzhou, China
Atridia Pty Ltd.Industry
NCT07358377 · 15 participants (planned) · Start May 15, 2026 · Primary completion Apr 10, 2027
Drug: HRS-6209 Capsules and fulvestrant injection · For: Breast Cancer
Sites: Bowral, Australia; Sydney, Australia; Elizabeth Vale, Australia · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Unresectable or Metastatic Breast Cancer
- HRS-2189Phase 23 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Breast Cancer, Prostate Cancer
- HRS-1358Phase 22 trials
Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
- HRS-9813Phase 22 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors, IPF and PPF
- FluvustatPhase 21 trial
Shandong Suncadia Medicine Co., Ltd. · Advanced Unresectable or Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.